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Personalized Advice to Sleep Apnea
Patients With Resistant Hypertension
Dreaming the Future*R. Doug McEvoy, MD,yz Michael Z. Michael, BSC (HONS), PHDxkO bstructive sleep apnea (OSA; deﬁned as>15 episodes of obstructive apnea andhypopnea per hour of sleep) was recently
estimated to affect 13% of men and 6% of women (1),
the prevalence having increased substantially over
the last 2 decades in parallel with rising rates of
obesity. OSA is associated with a 2- to 3-fold increase
in the risk of stroke, ischemic heart disease, heart fail-
ure, and sudden death (2). One of the main putative
mechanisms for increased OSA-related cardiovas-
cular risk is systemic hypertension. Epidemiological
studies have shown an independent association be-
tween OSA and prevalent and incident hypertension.
Nocturnal intermittent hypoxia induces a number
of neurophysiological and biochemical changes that
alter central neural control of blood pressure (BP) or
directly increase peripheral arterial smooth muscle
tone, leading to persistent BP elevation (3).
Continuous positive airway pressure (CPAP) treat-
ment of OSA lowers mean BP although the effect is
modest (w3 mm Hg) (4), in part because of subopti-
mal treatment adherence. In a head-to-head com-
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this paper to disclose.hypertensive patients with OSA, valsartan achieved
much better BP control (5). Pharmacotherapy is
therefore the preferred method for achieving BP
control in most OSA patients who are hypertensive.
OSA treatment may, however, assume greater
importance in managing the 15% of hypertensive
patients who have resistant hypertension (RH) (6).
Forty percent of patients in hypertension clinics have
OSA (7); however, this rises to w80% among patients
with RH (8). Indeed, OSA may be the most common
secondary cause of RH (9). For patients with RH,
pharmacological options have been exhausted, and
the impact of persistent hypertension on long-term
cardiovascular risk is great (10). Therefore, CPAP
treatment for OSA should be considered. Encourag-
ingly, the decrease in BP after CPAP treatment is
greater in OSA patients with RH than in those who
are drug responsive (11). However, the BP response
remains highly variable, with some patients showing
large treatment effects and others little to none.
Until now, there has been no way for clinicians to
distinguish between those who will and will not
respond to CPAP.SEE PAGE 1023In this issue of the Journal, Sánchez-de-la-Torre
et al. (12) report that BP responder status among OSA
patients with RH can be predicted by measuring the
plasma levels of 3 speciﬁc microribonucleic acids
(microRNAs). MicroRNAs are short, noncoding RNA
fragments that regulate fundamental biological pro-
cesses by affecting gene expression, generally at a
post-transcriptional level and by inhibiting trans-
lation of messenger RNAs into their protein products.
Early experiments showed that speciﬁc patterns of
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1034microRNA expression reﬂect cellular identity, which
led to microRNAs being used as powerful diagnostic
biomarkers of cancer (13). Later, it was discovered that
circulating microRNAs, which are remarkably stable in
blood due to protection from nuclease degradation
(14,15), may also reﬂect other disease states (16),
including various cardiovascular diseases (17,18).
Pertinent to the present study (12): circulating micro-
RNA patterns and levels can be markedly affected by
comorbid diseases (19) and may be sex-speciﬁc (20).
The authors initially measured 84 microRNAs
associated with human cardiovascular conditions in
baseline and follow-up plasma samples collected from
38 male OSA patients with RH who used CPAP >4 h/
night for 3 months in a controlled trial (21). A median
split was used to deﬁne CPAP BP “responder” and
“nonresponder” groups (median and interquartile BP
change: 11 [7.5, 14.1] vs. 0.25 [5, 2.5] mm Hg). Eight
differentially expressed microRNAs in baseline sam-
ples were chosen for further investigation, and in a
training set of 12 responders and 12 nonresponders,
the number of discriminatory microRNAs was further
reduced to 3 and optimal plasma cutoff levels deﬁned
using logistic regression. Areas under the receiver-
operating characteristic curve for the logistic regres-
sion model in the training set were 0.88 (95%
conﬁdence interval 0.75 to 1.00) and 0.92 (0.79 to
1.00) in a validation set, indicating good discrimina-
tory power. The logistic regression model was then
used to assign a numerical score of 1, 2, or 3 to the 3
microRNAs to create the HIPARCO score (range of
possible values 0 to 6). The investigators also examined
the CPAP treatment’s effect on the circulating levels of
cardiovascular-associated microRNAs in 5 responders
versus 5 nonresponders, and identiﬁed differences in 47
of the 84 microRNAs tested. Using bioinformatics, they
assigned these changes to putative pathways involved
in cardiovascular disease and cancer.
The microRNA HIPARCO score would thus appear
to be a novel, potentially useful test to help clinicians
decide whether to recommend CPAP therapy in OSA
patients with RH. Such a test could be particularly
helpful for the two-thirds of OSA patients who are
asymptomatic or only minimally sleepy and may not
accept CPAP unless some other major beneﬁt suchas sustained BP reduction can be guaranteed. How-
ever, there are some important study limitations to
consider. First, considerable caution needs to be
exercised given the small sample size, both in the
training set (n ¼ 22 with complete data) and the
validation set (n ¼ 14), as well as the inclusion of
men only, a limitation acknowledged by the authors.
The ﬁndings will thus need to be replicated in much
larger, more diverse patient populations where
proper adjustment can be made for comorbid disease
and will need to include women before the test is
ready for prime time. Future studies should also
include OSA patients with drug-responsive hyper-
tension to see whether the present results can be
extrapolated to predict a subgroup in which medica-
tions can be avoided or reduced. Secondly, although
the study results showed that low and high HIPARCO
scores had high predictive value for unfavorable
versus favorable CPAP responses, approximately
one-third of patients had scores of 2 or 3 that were
indeterminate. Future studies may show that addi-
tional biomarkers (e.g., from the renin-angiotensin
II-aldosterone pathway) will enhance its discrimina-
tory power.
Finally, when compiling lists of differentially
expressed genes or microRNAs, the temptation ex-
ists in such studies to infer the biological relevance
of such changes using bioinformatic predictions.
This study has also succumbed to this temptation;
however, it is important to recall that microRNAs
operate within a cellular context, their function(s)
reliant on the transcriptome of a given cell. The
relevance of such predictions, drawn from micro-
RNAs initially selected on the basis of their roles
in cardiovascular conditions, remains to be deter-
mined, given that their functionality as circulating
molecules is not deﬁned. Mechanistic studies will
be required to validate the relevance of the micro-
RNAs affected by CPAP to the pathophysiology of
hypertension.
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